Skip to main content

Table 3 Comparison of mortality in presence or absence of TACE during and after discontinuation of sorafenib administration

From: Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study

 

Sorafenib (+) TACE (+) vs. TACE (-)

 

Sorafenib (-) TACE (+) vs. TACE (-)

Subgroups

 

Subgroups

 

 Group I (n = 52)

14/21 vs. 28/31 p = 0.002*

Group I (n = 38)

6/10 vs. 24/28 p = 0.001*

 Group II (n = 58)

13/21 vs. 23/37 p = 0.595

Group II (n = 40)

4/10 vs. 23/30 p = 0.034*

 Group III (n = 46)

12/15 vs. 24/31 p = 0.074

Group III (n = 31)

3/6 vs. 20/25 p = 0.647

HCC-total Patients (N = 156)

39/57 vs. 75/99 p = 0.002*

HCC-total Patients (N = 109)

13/26 vs. 67/83 p = 0.001*

  1. Abbreviations: Group I always accepted 800 mg/day; Group II initially accepted 800 mg/day tapering to 400 mg/day owing to adverse events; Group III always accepted 400 mg/day. TACE transarterial chemoembolization
  2. *A P-value below 0.05 is considered statistically significant
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us